Kaken Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Kaken Pharmaceutical has a total shareholder equity of ¥154.4B and total debt of ¥3.9B, which brings its debt-to-equity ratio to 2.5%. Its total assets and total liabilities are ¥187.1B and ¥32.7B respectively. Kaken Pharmaceutical's EBIT is ¥23.6B making its interest coverage ratio -46.6. It has cash and short-term investments of ¥84.0B.
Key information
2.5%
Debt to equity ratio
JP¥3.85b
Debt
| Interest coverage ratio | -46.6x |
| Cash | JP¥83.99b |
| Equity | JP¥154.41b |
| Total liabilities | JP¥32.72b |
| Total assets | JP¥187.12b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: KKPC.F's short term assets (¥122.7B) exceed its short term liabilities (¥23.7B).
Long Term Liabilities: KKPC.F's short term assets (¥122.7B) exceed its long term liabilities (¥9.0B).
Debt to Equity History and Analysis
Debt Level: KKPC.F has more cash than its total debt.
Reducing Debt: KKPC.F's debt to equity ratio has reduced from 3.1% to 2.5% over the past 5 years.
Debt Coverage: KKPC.F's debt is well covered by operating cash flow (694.9%).
Interest Coverage: KKPC.F earns more interest than it pays, so coverage of interest payments is not a concern.